23andMe co-founder and CEO Anne Wokcicki won back control of the genetic-test company after a prolonged bankruptcy fight that at one point was won by Regeneron.

CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday.

Regeneron had previously been the winning bidder in a bankruptcy auction for virtually all of 23andMe’s assets, but it's now lost out after bidding was reopened. Back to Top Albany Business Review ...

A bankruptcy court this week approved the $305 million sale of genetics testing firm 23andMe to a nonprofit organization led by the company's former CEO Anne Wojcicki, the company announced. The ...

Walsh on Friday, marks the end of a monthslong bidding war between TTAM and Regeneron Pharmaceuticals — a biotech company that had previously agreed to buy most of 23andMe’s assets for $256 million in ...

Wojcicki and biotech company Regeneron are the final two bidders, ... The final round of bidding will occur later this week. “23andMe remains committed to protecting customer data.

Me’s privacy ombudsman secured court approval to retain WilmerHale in the DNA testing company’s Chapter 11 case despite an ...

The case came after New York-based biotech giant Regeneron Pharmaceuticals announced May 19 its plan to purchase 23andMe in a $256 million deal. That deal has since faced new challenges in ...

Regeneron will no longer be 23andMe’s new owner. Previously it had been reported that 23andMe’s new buyer, paying $256 million for the company’s assets, ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Regeneron Pharmaceuticals, ...